Sinusitis – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Sinusitis – Pipeline Review, H1 2017’, provides an overview of the Sinusitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sinusitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Sinusitis

– The report reviews pipeline therapeutics for Sinusitis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Sinusitis therapeutics and enlists all their major and minor projects

– The report assesses Sinusitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Sinusitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Sinusitis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Sinusitis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AmpliPhi Biosciences Corp

F. Hoffmann-La Roche Ltd

Knopp Biosciences LLC

Kyorin Pharmaceutical Co Ltd

Kyowa Hakko Kirin Co Ltd

Merck & Co Inc

OptiNose US Inc

Pfizer Inc

Quorum Innovations LLC

Regeneron Pharmaceuticals Inc

Therabron Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Sinusitis - Overview

Sinusitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Sinusitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Sinusitis - Companies Involved in Therapeutics Development

AmpliPhi Biosciences Corp

F. Hoffmann-La Roche Ltd

Knopp Biosciences LLC

Kyorin Pharmaceutical Co Ltd

Kyowa Hakko Kirin Co Ltd

Merck & Co Inc

OptiNose US Inc

Pfizer Inc

Quorum Innovations LLC

Regeneron Pharmaceuticals Inc

Therabron Therapeutics Inc

Sinusitis - Drug Profiles

ABPA-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABSA-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benralizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexpramipexole dihydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dupilumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fluticasone propionate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-0111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lascufloxacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PCL-1550 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06817024 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Qi-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-6149 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Sinusitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chronic Rhinosinusitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sinusitis - Dormant Projects

Sinusitis - Product Development Milestones

Featured News & Press Releases

Mar 07, 2017: Knopp Biosciences Announces Publication of Eosinophil-Lowering Effects of Dexpramipexole in Multiple Clinical Trials

Dec 19, 2016: AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01 in Chronic Rhinosinusitis Patients

Oct 25, 2016: AmpliPhi Biosciences Announces Favorable Topline Safety and Tolerability Results from Its Phase 1 Trial in Patients with Chronic Rhinosinusitis

Sep 20, 2016: AmpliPhi Biosciences Provides Update on Phase 1 Trial in Chronic Rhinosinusitis Patients

Sep 16, 2016: OptiNose Presents Data from Phase 3 Trials with Investigational Product Using Exhalation Delivery System Technology for Treatment in Patients with Chronic Rhinosinusitis with and without Nasal Polyps

Aug 09, 2016: AmpliPhi Biosciences Confirms Clinical Trial Progress

Aug 03, 2016: AmpliPhi Biosciences Completes Enrollment of Its Investigational Phage Therapy Trial Targeting Staphylococcus aureus

Apr 20, 2016: AmpliPhi Biosciences Provides Update on Phase I Trial: Phage Therapy Well Tolerated in First Cohort

Feb 03, 2016: Nasal polyps can be treated with medicine dupilumab

Feb 02, 2016: Sanofi and Regeneron Announce Publication of Positive Phase 2 Dupilumab Data in the Journal of the American Medical Association

Jan 20, 2016: AmpliPhi Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial of AB-SA01

Nov 19, 2015: AmpliPhi Signs Clinical Trial Agreement with University of Adelaide to Conduct a Phase I Trial of Bacteriophage Therapy for Treating Staphylococcus aureus Infections

Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets

Sep 30, 2014: Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Sinusitis, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Sinusitis – Pipeline by AmpliPhi Biosciences Corp, H1 2017

Sinusitis – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Sinusitis – Pipeline by Knopp Biosciences LLC, H1 2017

Sinusitis – Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017

Sinusitis – Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017

Sinusitis – Pipeline by Merck & Co Inc, H1 2017

Sinusitis – Pipeline by OptiNose US Inc, H1 2017

Sinusitis – Pipeline by Pfizer Inc, H1 2017

Sinusitis – Pipeline by Quorum Innovations LLC, H1 2017

Sinusitis – Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Sinusitis – Pipeline by Therabron Therapeutics Inc, H1 2017

Sinusitis – Dormant Projects, H1 2017

List of Figures

List of Figures

Number of Products under Development for Sinusitis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports